Search results for "Roi"

showing 10 items of 11055 documents

Prognosis and cure of long-term cancer survivors: A population-based estimation.

2019

Background: Increasing evidence of cure for some neoplasms has emerged in recent years. The study aimed to estimate population-based indicators of cancer cure. Methods: Information on more than half a million cancer patients aged 15-74 years collected by population-based Italian cancer registries and mixture cure models were used to estimate the life expectancy of fatal tumors (LEFT), proportions of patients with similar death rates of the general population (cure fraction), and time to reach 5-year conditional relative survival (CRS) >90% or 95% (time to cure). Results: Between 1990 and 2000, the median LEFT increased >1 year for breast (from 8.1 to 9.4 years) and prostate cancers (from 5.…

0301 basic medicineOncologyMaleCancer ResearchTime FactorsSettore MED/42 - Igiene Generale E Applicata0302 clinical medicineCancer SurvivorsProstateNeoplasmsThyroid cancerOriginal Researcheducation.field_of_studyRelative survivalMortality rateMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosispopulation-based cancer registriemedicine.anatomical_structureOncologyItaly030220 oncology & carcinogenesiscancer cure Italy population-based cancer registries prevalence survivalFemaleCancer PreventionAdultmedicine.medical_specialtypopulation-based cancer registriesAdolescentPopulationprevalenceSocio-culturalelcsh:RC254-282survival03 medical and health sciencesYoung AdultLife ExpectancyInternal medicinemedicinepopulation‐based cancer registriesHumansRadiology Nuclear Medicine and imagingcancer cureeducationAgedEstimationbusiness.industryCancerModels Theoreticalmedicine.disease030104 developmental biologyLife expectancycancer cure; Italy; population-based cancer registries; prevalence; survivalbusinessCancer medicine
researchProduct

Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highli…

2017

Abstract Background Preclinical models that mimic pathological and molecular features of solitary fibrous tumour (SFT) represent an important tool to select effective regimes and novel compounds to be tested in the clinic. This study was aimed at developing two preclinical models of SFT, assessing their predictive value in the clinic and selecting potential novel effective treatments. Material and methods Two dedifferentiated-SFT (D-SFT) models obtained from patients' biopsies were grown in immunodeficient mice. The antitumour activity on these models of doxorubicin, dacarbazine (DTIC), ifosfamide (monotherapy or combination), trabectedin and eribulin was tested. Twelve SFT patients were tr…

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_treatmentSolitary fibrous tumourSoft Tissue NeoplasmsDioxoleMice SCIDPharmacologyAnthracyclineMetastasichemistry.chemical_compound0302 clinical medicineSolitary Fibrous TumorRetrospective StudieTetrahydroisoquinolinesAntineoplastic Combined Chemotherapy ProtocolsTetrahydroisoquinolineMeningeal NeoplasmsMeningeal NeoplasmPleural NeoplasmTrabectedinIfosfamideKidney NeoplasmSarcomaKetonesMiddle AgedMice modelKetoneKidney NeoplasmsDacarbazineSurvival RateOncologyResponse Evaluation Criteria in Solid TumorsSolitary Fibrous Tumors030220 oncology & carcinogenesisFemalemedicine.drugEribulinHumanAdultmedicine.medical_specialtyXenograft Model Antitumor AssayAnthracyclinePleural NeoplasmsDacarbazineBlotting WesternResponse Evaluation Criteria in Solid TumorDioxolesDisease-Free Survival03 medical and health sciencesInternal medicinemedicineAnimalsHumansChemotherapyFuranDoxorubicinRetroperitoneal NeoplasmsEribulinIfosfamideSoft Tissue NeoplasmCerebellar NeoplasmsFuransResponse Evaluation Criteria in Solid TumorsRetrospective StudiesAgedChemotherapyAntineoplastic Combined Chemotherapy ProtocolRetroperitoneal Neoplasmbusiness.industryAnimalXenograftCerebellar NeoplasmXenograft Model Antitumor AssaysTreatment030104 developmental biologychemistryDoxorubicinbusinessTrabectedin
researchProduct

Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting

2018

The eighth annual conference of “Innovative therapy, monoclonal antibodies, and beyond” was held in Milan on Jan. 26, 2018, and hosted by Fondazione IRCCS–Istituto Nazionale dei Tumori (Fondazione IRCCS INT). The conference was divided into two main scientific sessions, of i) pre-clinical assays and novel biotargets, and ii) clinical translation, as well as a third session of presentations from young investigators, which focused on recent achievements within Fondazione IRCCS INT on immunotherapy and targeted therapies. Presentations in the first session addressed the issue of cancer immunotherapy activity with respect to tumor heterogeneity, with key topics addressing: 1) tumor heterogeneit…

0301 basic medicineOncologyTumor heterogeneitymedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and Metabolismmedicine.medical_treatmentImmunologyMonoclonal antibodyGeneral Biochemistry Genetics and Molecular BiologyTargeted therapyTargeted therapy03 medical and health sciences0302 clinical medicineImmune systemCancer immunotherapyInternal medicineImmunology and AllergyMedicineAnimalbusiness.industryMicrobiotaRepertoireMelanomaImmune checkpoints inhibitionAntibodies MonoclonalImmunotherapymedicine.diseaseCancer metabolismGastrointestinal MicrobiomeRadiation therapy030104 developmental biologyCancer stemness signaling030220 oncology & carcinogenesisNeoplasmImmunotherapybusinessHumanCytokine & Growth Factor Reviews
researchProduct

Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists.

2018

The use of immune checkpoint inhibitors constitutes an emerging therapeutic field for the therapy of gastrointestinal (GI) malignancies following the recent FDA approvals of PD-1 inhibitors for esophago-gastric adenocarcinoma, hepatocellular carcinoma and for microsatellite-instable tumors, which are mainly colorectal cancers. This paper reviews the clinical evidence end of 2017 and discusses the clinical development programs of atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab in GI-tract cancers. Since 2014, these antagonists of the PD-1/PD-L1 axis have gained approval for use in numerous other tumors. Phase II trials and phase I expansion cohorts demonstrate clinical activi…

0301 basic medicineOncologymedicine.medical_specialtyDurvalumabColorectal cancerProgrammed Cell Death 1 ReceptorPembrolizumabB7-H1 AntigenAvelumab03 medical and health sciences0302 clinical medicineAtezolizumabInternal medicinemedicineHumansGastrointestinal Neoplasmsbusiness.industryCancerAntibodies MonoclonalHematologymedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisAdenocarcinomaImmunotherapyNivolumabbusinessmedicine.drugCritical reviews in oncology/hematology
researchProduct

Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice

2017

Background: Regorafenib (REG) has now been approved as the standard third-line therapy in metastatic gastrointestinal stromal tumour (GIST) patients at the recommended dose and schedule of 160 mg once daily for the first 3 weeks of each 4-week cycle. However, it has a relevant toxicity profile that mainly occurs within the first cycles of therapy, and dose and schedule adjustments are often required to reduce the frequency or severity of adverse events and to avoid early treatment discontinuation. To date, large amounts of data on the use of REG in metastatic GIST patients in daily clinical practice are not available, and we lack information about how this treatment personalization really a…

0301 basic medicineOncologymedicine.medical_specialtyScheduleStromal cellSettore MED/06 - Oncologia Medicalcsh:RC254-282PersonalizationNO03 medical and health scienceschemistry.chemical_compound0302 clinical medicinetyrosine kinase inhibitorQuality of lifeInternal medicineRegorafenibtyrosine kinase inhibitorsmedicineOriginal Researchreferral centresGiSTbusiness.industryGIST; personalized treatment; quality of life; referral centres; regorafenib; tyrosine kinase inhibitors; OncologyGastrointestinal stromal tumourslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenspersonalized treatmentClinical PracticeGIST; personalized treatment; quality of life; referral centres; regorafenib; tyrosine kinase inhibitorsreferral centre030104 developmental biologychemistryquality of lifeOncology030220 oncology & carcinogenesisregorafenibbusinessGIST personalized treatment quality of life referral centres regorafenib tyrosine kinase inhibitorsGIST
researchProduct

Mid-region parathyroid hormone-related protein is a genome-wide chromatin-binding factor that promotes growth and differentiation of HB2 epithelial c…

2018

Human parathyroid hormone-related protein (PTHrP) is a polyhormone that undergoes proteolytic cleavage producing smaller peptides which exert diversified biological effects. PTHrP signalization is prominently involved in breast development and physiology, but the studies have been focused onto either N-terminal species or full-length protein introduced by gene transfer techniques. Our present work investigates for the first time the effect of the mid-region PTHrP secretory form, that is, the fragment [38-94], on HB2 non-tumoral breast epithelial cells. We examined viability/proliferation of cells grown in PTHrP-containing media supplemented with different serum concentration and on differen…

0301 basic medicinePTHrPCellClinical BiochemistryBiochemistryCell Line03 medical and health sciences0302 clinical medicineCell Line TumorGene expressionmedicineHumanscell growthBinding siteSettore BIO/06 - Anatomia Comparata E CitologiaCell ProliferationParathyroid hormone-related proteinChemistryCell growthChromatin bindingParathyroid Hormone-Related ProteinCell DifferentiationEpithelial CellsGeneral MedicineChromatinCell biologychromosome decorationSettore BIO/18 - Genetica030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisbreast cellgene expressionMolecular MedicineFemaleReprogramminghormones hormone substitutes and hormone antagonists
researchProduct

Vitamin D and Its Analogues Decrease Amyloid-β (Aβ) Formation and Increase Aβ-Degradation

2017

Alzheimer’s disease (AD) is characterized by extracellular plaques in the brain, mainly consisting of amyloid-β (Aβ), as derived from sequential cleavage of the amyloid precursor protein. Epidemiological studies suggest a tight link between hypovitaminosis of the secosteroid vitamin D and AD. Besides decreased vitamin D level in AD patients, an effect of vitamin D on Aβ-homeostasis is discussed. However, the exact underlying mechanisms remain to be elucidated and nothing is known about the potential effect of vitamin D analogues. Here we systematically investigate the effect of vitamin D and therapeutically used analogues (maxacalcitol, calcipotriol, alfacalcidol, paricalcitol, doxercalcife…

0301 basic medicineParicalcitolPlaque Amyloidvitamin Damyloid precursor proteinlcsh:ChemistrySecosteroidMicechemistry.chemical_compound0302 clinical medicinevitamin D analoguesvitamin D; vitamin D analogues; amyloid precursor protein; amyloid-β; secretases; Aβ-degradationAmyloid precursor proteinlcsh:QH301-705.5CalcipotriolSpectroscopybiologysecretasesBrainAlfacalcidolVitaminsGeneral Medicine3. Good healthComputer Science ApplicationsFemalemedicine.drugmedicine.medical_specialtyAβ-degradationNicastrinamyloid-βArticleCatalysisInorganic Chemistry03 medical and health sciencesCell Line TumorInternal medicinemedicineVitamin D and neurologyAnimalsHumansPhysical and Theoretical ChemistryMolecular BiologyAmyloid beta-PeptidesOrganic ChemistryMice Inbred C57BL030104 developmental biologyEndocrinologylcsh:Biology (General)lcsh:QD1-999chemistryProteolysisbiology.proteinAmyloid Precursor Protein SecretasesAmyloid precursor protein secretase030217 neurology & neurosurgeryInternational Journal of Molecular Sciences
researchProduct

Intestinal dysbiosis and innate immune responses in axial spondyloarthritis

2016

Purpose of review Inflammatory innate and adaptive immune cell responses to commensal bacteria underlie the pathogenesis of human chronic inflammatory diseases. Intestinal dysbiosis has been described in patients with spondyloarthritis (SpA) and seems to be correlated with histologic and immunologic alterations. Purpose of this review is to discuss the relationship occurring between intestinal dysbiosis and innate immune responses in patients with axial SpA. Recent findings Intestinal dysbiosis and differential activation of intestinal immune responses in patients with SpA have been demonstrated. Furthermore, innate cells that appear to be involved in the pathogenesis of SpA may control int…

0301 basic medicinePathogenesis03 medical and health sciences0302 clinical medicineImmune systemRheumatologyImmunityIL-23dysbiosis; gut inflammation; IL-17; IL-23; IL-9; innate lymphoid cells; spondyloarthritis; RheumatologySpondylarthritisInterleukin 23MedicineHumansspondyloarthriti030203 arthritis & rheumatologyInnate immune systemBacteriabusiness.industrydysbiosiInnate lymphoid cellmedicine.diseaseIL-9Immunity InnateGastrointestinal MicrobiomeIntestinesIL-17030104 developmental biologyImmunologyinnate lymphoid cellDysbiosisInterleukin 17gut inflammationbusinessDysbiosis
researchProduct

Quantitative immunomorphological analysis of heat shock proteins in thyroid follicular adenoma and carcinoma tissues reveals their potential for diff…

2019

Hsp27, Hsp60, Hsp70, and Hsp90 are chaperones that play a crucial role in cellular homeostasis and differentiation, but they may be implicated in carcinogenesis. Follicular neoplasms of the thyroid include follicular adenoma and follicular carcinoma. The former is a very frequent benign encapsulated nodule, whereas the other is a nodule that infiltrates the capsule, blood vessels and the adjacent parenchyma, with a tendency to metastasize. The main objective was to assess the potential of the Hsps in differential diagnosis and carcinogenesis. We quantified by immunohistochemistry Hsp27, Hsp60, Hsp70, and Hsp90 on thin sections of human thyroid tissue with follicular adenoma or follicular ca…

0301 basic medicinePathologyCellular homeostasismedicine.disease_causechaperonopathieslcsh:TechnologyHsp70lcsh:Chemistry0302 clinical medicineFollicular phasedifferential diagnosisGeneral Materials ScienceHsp27Instrumentationlcsh:QH301-705.5CarcinogenesiFluid Flow and Transfer ProcessesThyroidThyroidGeneral EngineeringHsp60Follicular adenomalcsh:QC1-999Computer Science Applicationsmedicine.anatomical_structure030220 oncology & carcinogenesisMolecular chaperoneImmunohistochemistrycarcinogenesismedicine.medical_specialtyendocrine systemanimal structuresAdenomaDifferential diagnosiHsp90BiologyFollicular carcinoma03 medical and health sciencesParenchymaCarcinomamedicinelcsh:TProcess Chemistry and Technologymedicine.disease030104 developmental biologylcsh:Biology (General)lcsh:QD1-999lcsh:TA1-2040ChaperonopathieCarcinogenesislcsh:Engineering (General). Civil engineering (General)lcsh:Physics
researchProduct

Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours

2017

Distinguishing between follicular thyroid cancer (FTC) and follicular thyroid adenoma (FTA) constitutes a long-standing diagnostic problem resulting in equivocal histopathological diagnoses. There is therefore a need for additional molecular markers. To identify molecular differences between FTC and FTA, we analyzed the gene expression microarray data of 52 follicular neoplasms. We also performed a meta-analysis involving 14 studies employing high throughput methods (365 follicular neoplasms analyzed). Based on these two analyses, we selected 18 genes differentially expressed between FTA and FTC. We validated them by quantitative real-time polymerase chain reaction (qRT-PCR) in an independe…

0301 basic medicinePathologyMicroarrayThyroid Glandlaw.inventionlawFollicular phaseGene expressionAdenocarcinoma Follicularfollicular thyroid adenoma; follicular thyroid cancer; gene expression; microarray; meta-analysisSpectroscopyPolymerase chain reactionOligonucleotide Array Sequence Analysisfollicular thyroid cancerGeneral MedicineCANCERComputer Science ApplicationsGene Expression Regulation NeoplasticCARCINOMASFUSION ONCOGENEmicroarrayNEOPLASMSmedicine.medical_specialtyMOLECULAR MARKERSASPIRATIONBiologyCatalysisCLASSIFICATIONArticleInorganic Chemistry03 medical and health sciencesNODULESADENOMASmedicineBiomarkers TumorHumansRNA MessengerThyroid NeoplasmsPhysical and Theoretical ChemistryFollicular thyroid cancerMolecular BiologyGeneGene Expression ProfilingOrganic ChemistryThyroid adenomaACVRL1medicine.diseaseMODELmeta-analysis030104 developmental biologyfollicular thyroid adenomaMutationgene expressionInternational Journal of Molecular Sciences
researchProduct